In a laboratory in China, scientists have engineered a vaccine that could fundamentally reshape how the world fights one of its most fearsome viruses. The vaccine, called [GPs+NP]@LNP, uses messenger RNA technology to train the immune system against multiple deadly strains of Ebola simultaneously—a breakthrough that addresses a critical gap in global disease defense, where current licensed vaccines target only a single Ebola species.
The challenge is profound and urgent. Ebola virus disease kills about half of those infected, triggering fever, vomiting, internal bleeding, and organ failure through direct contact with infected blood or bodily fluids. Right now, only two licensed Ebola vaccines exist worldwide, and both focus exclusively on Zaire ebolavirus, leaving populations vulnerable to other lethal strains like Bundibugyo, which is currently spreading across the Democratic Republic of Congo and Uganda. For years, researchers have known an all-in-one vaccine was needed. Now, a team from China has delivered one.
The approach borrows from the same mRNA technology that proved its worth during the COVID-19 pandemic. Rather than injecting a live or weakened virus, [GPs+NP]@LNP delivers genetic instructions that teach the body's cells to produce specific viral proteins from multiple Ebola strains. The genius lies in what the researchers selected: three surface glycoproteins—the outer spikes viruses use to invade human cells—combined with one nucleoprotein, an internal structural protein that remains nearly identical across all Ebola variants. The glycoproteins trigger protective antibodies, while the nucleoprotein activates killer T cells that hunt down and destroy cells already infected. As the study authors explained, this combination creates "both strong antibody responses and cellular immunity with high compatibility between GPs and NP."
In preclinical trials, the results were striking. Mice vaccinated against Ebola virus showed 100% survival with strong viral clearance in blood, liver, and spleen. The vaccine reduced viral loads in mice exposed to Bundibugyo virus, while hamsters exposed to Sudan virus maintained stable weight and eliminated all circulating virus from their blood. One of the most remarkable findings: protection lasted approximately 17 months after vaccination in mice—suggesting the immunity could be enduring rather than fleeting.
"These findings highlight [GPs+NP]@LNP as a promising approach for the development of next-generation vaccines targeting multiple pathogenic orthoebolaviruses," the research team concluded in their paper, published in the Proceedings of the National Academy of Sciences.
But important work remains before this vaccine reaches people in danger. The researchers acknowledge that the next phase requires testing in higher-order animal models, particularly non-human primates, before any human clinical trials can begin. Still, the progress is unmistakable. In a world where Ebola outbreaks occur unpredictably and spread with devastating speed, a vaccine that provides broad protection across multiple strains represents the kind of scientific advance that could save thousands of lives and offer hope to communities living under the shadow of this virus.